Chemodenervation Grant Winners
Funded by the Allergan Foundation
2021
Kelly Ieong, Stony Brook University Hospital
Incidence and impact of antibodies against OnabotulinumtoxinA (Botox) on treatment efficacy in patients with idiopathic overactive bladder (OAB): a pilot study
2020
Megan Bradley, MD, University of Pittsburgh
Whole-Exome Sequencing in Women with Refractory Overactive Bladder: Biomarker Prediction of Treatment Response
2019
Hatim Thaker, MD, Boston Children's Hospital/Harvard Medical School
In Vivo Efficacy of Botulinum Neurotoxins on a Novel Preclinical Mouse Model
2019
Whitney K. Hendrickson, MD, Duke University Health System
Model for Predicting Efficacy of Treatment and Complications in Women after Intradetrusor OnabotulinumtoxinA for NonNeurogenic Urgency Incontinence
2018
Esther Han, DO, Beaumont Health, Michigan
Is Less More? Does Decreasing OnabotulinumtoxinA Injection Sites in the Bladder Increase Patient Satisfaction While Maintaining Efficacy?
2018
Temitope Rude, MD, University of Southern California, Los Angeles, CA
Access to OnabotulinumtoxinA Treatment in Neurogenic Detrusor Overactivity
2018
R. Trafford Crump, PhD, University of Calgary, Calgary, Alberta, Canada
The Use of Chemodenervation to Treat Overactive Bladder in Elderly Patients
2018
Unwanaobong Nseyo, MD, MHS, UC San Diego, San Diego, CA
Multicenter, Prospective Evaluation of Intradetrusor Injections of Botulinum Toxin-A in an Adult Myelomeningocele Population
2017
Rachel Sosland, MD, Vanderbilt University Medical Center, Nashville, TN
Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection: A Non-Inferiority Trial
2017
Raveen Syan, MD, Stanford University, Stanford, CA
Feasibility and Efficacy of Transvaginal OnabotulinumtoxinA Chemodenervation of the Trigone for the Third Line Treatment of Refractory Overactive Bladder
2016
Yingchun Zhang, PhD, University of Houston, Houston, TX
QUANTITATIVE MAPPING OF THE HYPERTONICITY OF THE PELVIC FLOOR MUSCLES USING HIGH-DENSITY SURFACE EMG
2016
Jessica C. Lloyd, MD, Cleveland Clinic, Cleveland, OH
A PROSPECTIVE COHORT TRIAL OF PELVIC FLOOR CHEMODENERVATION IN PATIENTS UNDERGOING PHYSICAL THERAPY FOR HIGH TONE PELVIC FLOOR DYSFUNCTION
2016
A. Lenore Ackerman, MD, PhD, Cedars-Sinai Medical Center, Beverly Hills, CA
THE MICROBIOME AS A PREDICTOR OF OUTCOMES OF INTRAVESICAL BOTULINUM TOXIN INJECTION
2015
Amy Dobberfuhl, Stanford University School of Medicine
LOCALIZATION OF ONABOTULINUMTOXINA AND CYSTOMETRIC RESPONSE FOLLOWING SINGLE VERSUS MULTIPLE INJECTIONS FOR THE TREATMENT OF OVERACTIVE BLADDER IN A RAT MODEL
2015
Rose Khavari, Houston Methodist Hospital
EVALUATION OF CENTRAL INHIBITORY EFFECTS OF INTRAVESICAL INJECTION OF BOTULINUM TOXIN A IN PATIENTS WITH NEUROGENIC AND NON-NEUROGENIC DETRUSOR OVERACTIVITY
2015
Paholo Barboglio Romo, University of Michigan
ONABOTULINUM TOXIN REPEATED INJECTIONS IN CERVICAL SPINAL CORD INJURY
2014
Brooke Brown, Fellow, Vanderbilt University
EFFECTS OF BLADDER ONABOTULINUM TOXIN INJECTION ON CENTRAL SENSITIZATION IN OAB PATIENTS.
2014
Andrea Russo, Fellow, Yale University
CHEMODENERVATION WITH ONABOTULINUMTOXINA AND ITS EFFECT ON BLADDER UROTHELIAL FUNCTION
2014
Eliza Lamin, Resident; Lisa Parrillo, Resident, University of Pennsylvania
COMPARISON OF THE TREATMENT OF REFRACTORY BLADDER PAIN SYNDROME WITH DIMETHYL SULFOXIDE (DMSO) ALONE AND DMSO AS A CARRIER FOR BOTULINUM TOXIN A INSTILLATION